PDCD1 and neoplasm: The recruitment of dysfunctional tumor-infiltrating PD-1+ TADCs with high expression of inflammatory cytokines/chemokines and PD-L1 weakens the immunotherapeutic response by PD-1/PD-L1 blockade and induces pembrolizumab resistance in cervical cancer [62].